Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia

Leukemia

Volumn 11, Issue 2, 1997, Pages 175-180

  Momparler, R L ^a   Cote S ^b   Eliopoulos, N ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NONE

Author keywords

5 Aza 2' deoxycytidine; Chemotherapy; DNA methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTILEUKEMIC AGENT;

CELL CYCLE PARAMETERS; DNA METHYLATION; DOSE CALCULATION; DRUG DOSE; GRANULOCYTOPENIA; HUMAN; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; SHORT SURVEY; TOXICITY;

EID: 0031045307     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400550     Document Type: Short Survey

References (14)

1. Sorm F, Vesely J. Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 1968; 15: 339-343.
2. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-Aza-2′-deoxycytidine, 1-β-D-arabinofuranosyl-cytosine and 5-azacytidine against L1210 leukemia. Leukemia Res 1984; 8: 1043-1049.
3. Estey E, Keating MJ, Plunkett W, McCredie KB, Freireich EJ. Continuous infusion of high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Semin Oncol 1987; 14 (Suppl. 2): 58-63.
4. Momparler RL, Onetto-Pothier N, Momparler LF. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2′-deoxycytidine against human leukemic cells of different phenotype. Leukemia Res 1990; 14: 755-760.
5. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin KT, Momparler LF. Phase I study on 5-Aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res 1981; 5: 453-462.
6. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-Aza-2-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1986; 30: 277-286.
7. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukaemic activity of 5-Aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer 1991; 64: 144-148.
8. Zagonel V, Giovanni LR, Maotta G, Babare R, Sardeo G, Gattie V, De Angelis V, Monfardini S, Pinto A. 5-Aza-2-deoxycytidine (Decitabine) induces trilineage response in unfavorable myelodysplastic syndromes. Leukemia 1993; 7 (Suppl. 1): 30-35.
9. Momparler RL, Onetto N. Drug resistance to cytosine arabinoside. In: D Kessel (ed.). Resistance to Antineoplastic Drugs. CRC Press: Boca Raton, 1988, pp 354-367.
10. Momparler RL, Momparler LF. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2′-deoxycytidine and 3-deazauridine. Cancer Chemother Pharmacol 1989; 25: 51-54.
11. Bouchard J, Momparler RL. Incorporation of 5-aza-2′-deoxycytidine 5′-triphosphate into DNA interactions with mammalian DNA polymerase and DNA methylase. Mol Pharmacol 1983; 24: 109-114.
12. Müller WEG, Zahn RK. Metabolism of 1-β-D-arabinofuranosyluracil in mouse L5178Y cells. Cancer Res 1979; 39: 1102-1107.
13. Onetto N, Momparler RL, Momparler LF, Gyger M. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-aza-2′-deoxycytidine. Semin Oncol 1987; 14: 231-237.
14. Eliopoulos N, Bovenzi V, Momparler LF, Cournoyer D, Momparler RL. Gene transfer of human cytidine deaminase cDNA into murine cells confers resistance to cytosine arabinoside, 5-aza-2′-deoxycytidine and 2,2′-difluorodeoxycytidine. 9th NCI-EORTC symposium on new drugs in cancer therapy. Ann Oncol 1996; 7 (Suppl. 1): 58.